NASDAQ
SUPN
Last Price
US $46.66
KEY FIGURES
MKT CAP
$2.7B
EPS
TTM
$-0.50
PEG
TTM
N/M
P/E
TTM
N/M
P/S
TTM
3.46x
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Supernus Pharmaceuticals, Inc. cash flow to debt ratio of 115.51% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial risk - Healthy cash flow growth.
Supernus Pharmaceuticals, Inc.'s free cash flow has decreased -73.14% from $171.23M last year to $45.99M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Supernus Pharmaceuticals, Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Supernus Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.03 last year to 0.04 today, signaling weakened financials
Financial stability - Net debt/EBITDA.
Supernus Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Supernus Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Supernus Pharmaceuticals, Inc.'s profit margin has decreased (-133.47%) in the last year from 11.16% to -3.74%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Supernus Pharmaceuticals, Inc.'s short-term assets of $644.18M exceed its short-term liabilities of $338.17M
Decreasing performance - ROA.
Supernus Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Supernus Pharmaceuticals, Inc.'s return on equity of -2.73%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Supernus Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Increasing performance - Earnings stability.
Supernus Pharmaceuticals, Inc. had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Supernus Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Decreasing performance - FCF yield.
Supernus Pharmaceuticals, Inc. has a free cash flow yield of 1.70%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Decreasing performance - Healthy earnings growth.
Supernus Pharmaceuticals, Inc.'s yearly earnings has decreased -152.19% since last year from $73.86M to $-38.55M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Supernus Pharmaceuticals, Inc.'s yearly revenue has increased 8.63% since last year from $661.82M to $718.95M, signaling increasing performance
Decreasing performance - ROIC.
ROIC -2.16% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Supernus Pharmaceuticals, Inc.'s 3-year revenue CAGR of 2.52% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Supernus Pharmaceuticals, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Supernus Pharmaceuticals, Inc. had positive ROE in 4.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Supernus Pharmaceuticals, Inc. is overvalued relative to its fair value price of 5.41 based on Discounted Cash Flow model
Overvalued - Earnings yield.
Supernus Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Supernus Pharmaceuticals, Inc. is overvalued relative to its fair value price of 6.51 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Supernus Pharmaceuticals, Inc. has an EV/EBITDA ratio of 61.61x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings
Overvalued - PEG ratio value.
Supernus Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Supernus Pharmaceuticals, Inc. has a price-to-book ratio of 2.50x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Supernus Pharmaceuticals, Inc. has a price-to-sales ratio of 3.46x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-2.73%
Return on equity
ROIC: -2.16%
Valuation History
-94.8X
Price to Earnings
EV/EBITDA: 51.6X
Cash flow
Profit margin
6.68%
(FY vs FY)
EBITDA Y/Y
-27.38%
(FY vs FY)
Cash flow Y/Y
-19.37%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $46.66
-88.41%
Default assumptions
EBITDA Multiple
Fair Value
Market $46.66
-86.05%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.